海南瑞澤(002596.SZ):回購註銷補償股份164.32萬股
格隆匯5月21日丨海南瑞澤(002596.SZ)公佈,根據海南瑞澤與徐湛元、鄧雁棟簽訂的《資產購買協議》以及《資產購買協議之補充協議》,鑑於標的公司廣東綠潤2019年度未能完成其承諾的盈利目標。交易對方徐湛元、鄧雁棟兩名股東將以其持有的公司股份進行業績補償。經計算,上述應補償股份合計數量為164.32萬股,佔回購註銷前公司股本總數的比例為0.1428%。其中徐湛元補償股份數量為83.2027萬股,鄧雁棟補償股份數量為81.1173萬股。公司按總價人民幣1.00元的價格回購補償股份並進行註銷。
經中國證券登記結算有限責任公司深圳分公司審核確認,公司本次股份回購註銷事宜已於2020年5月20日辦理完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.